{"corpus_id":4228513,"paper_sha":"cf40794b608f0889c4f2db31faa351d71841688a","doi":"10.1074/jbc.RA117.000950","arxiv_id":null,"pmid":29382728,"pmcid":"PMC5868245","mag_id":2786643981,"dblp_id":null,"acl_id":null,"title":"The curcumin analog HO-3867 selectively kills cancer cells by converting mutant p53 protein to transcriptionally active wildtype p53","year":2018,"publication_date":"2018-01-30","venue":"Journal of Biological Chemistry","journal":{"name":"The Journal of Biological Chemistry","pages":"4262 - 4276","volume":"293"},"journal_issn":null,"journal_title":null,"publication_types":["JournalArticle"],"pubmed_pub_types":["Journal Article","Research Support, Non-U.S. Gov't"],"s2_fields_of_study":["Medicine","Chemistry"],"reference_count":70,"citation_count":40,"influential_citation_count":3,"is_open_access":true,"arxiv_categories":null,"arxiv_license":null,"arxiv_journal_ref":null,"mesh_headings":[{"d":"Animals","mj":false,"ui":"D000818"},{"d":"Antineoplastic Agents","mj":false,"qs":[{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D000970"},{"d":"Apoptosis","mj":false,"qs":[{"q":"drug effects","mj":true,"ui":"Q000187"}],"ui":"D017209"},{"d":"Cell Proliferation","mj":false,"qs":[{"q":"drug effects","mj":false,"ui":"Q000187"}],"ui":"D049109"},{"d":"Curcumin","mj":false,"qs":[{"q":"analogs & derivatives","mj":true,"ui":"Q000031"},{"q":"pharmacology","mj":false,"ui":"Q000494"}],"ui":"D003474"},{"d":"Female","mj":false,"ui":"D005260"},{"d":"Humans","mj":false,"ui":"D006801"},{"d":"Mice","mj":false,"ui":"D051379"},{"d":"Mice, Nude","mj":false,"ui":"D008819"},{"d":"Mutant Proteins","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D050505"},{"d":"Mutation","mj":true,"ui":"D009154"},{"d":"Neoplasms","mj":false,"qs":[{"q":"drug therapy","mj":false,"ui":"Q000188"},{"q":"genetics","mj":false,"ui":"Q000235"},{"q":"pathology","mj":true,"ui":"Q000473"}],"ui":"D009369"},{"d":"Piperidones","mj":false,"qs":[{"q":"pharmacology","mj":true,"ui":"Q000494"}],"ui":"D010881"},{"d":"Tumor Cells, Cultured","mj":false,"ui":"D014407"},{"d":"Tumor Suppressor Protein p53","mj":false,"qs":[{"q":"genetics","mj":true,"ui":"Q000235"},{"q":"metabolism","mj":false,"ui":"Q000378"}],"ui":"D016159"},{"d":"Xenograft Model Antitumor Assays","mj":false,"ui":"D023041"}],"chemicals":[{"n":"(3,5-bis((4-fluorophenyl)methylidene)-1-((1-hydroxy-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl)piperidin-4-one)","ui":"C541427","reg":"0"},{"n":"Antineoplastic Agents","ui":"D000970","reg":"0"},{"n":"Mutant Proteins","ui":"D050505","reg":"0"},{"n":"Piperidones","ui":"D010881","reg":"0"},{"n":"TP53 protein, human","ui":"C495901","reg":"0"},{"n":"Tumor Suppressor Protein p53","ui":"D016159","reg":"0"},{"n":"Curcumin","ui":"D003474","reg":"IT942ZTH98"}],"comments_corrections":null,"source_flags":5,"s2_open_access_pdf_url":"http://www.jbc.org/article/S002192582039801X/pdf","s2_open_access_landing_url":"https://www.semanticscholar.org/paper/cf40794b608f0889c4f2db31faa351d71841688a","s2_open_access_license":"CCBY","s2_open_access_status":"HYBRID","pmc_open_access_pdf_url":null,"pmc_open_access_landing_url":null,"pmc_open_access_license":null,"pmc_open_access_status":null,"unpaywall_open_access_pdf_url":null,"unpaywall_open_access_landing_url":null,"unpaywall_open_access_license":null,"unpaywall_open_access_status":null,"abstract":"p53 is an important tumor-suppressor protein that is mutated in more than 50% of cancers. Strategies for restoring normal p53 function are complicated by the oncogenic properties of mutant p53 and have not met with clinical success. To counteract mutant p53 activity, a variety of drugs with the potential to reconvert mutant p53 to an active wildtype form have been developed. However, these drugs are associated with various negative effects such as cellular toxicity, nonspecific binding to other proteins, and inability to induce a wildtype p53 response in cancer tissue. Here, we report on the effects of a curcumin analog, HO-3867, on p53 activity in cancer cells from different origins. We found that HO-3867 covalently binds to mutant p53, initiates a wildtype p53-like anticancer genetic response, is exclusively cytotoxic toward cancer cells, and exhibits high anticancer efficacy in tumor models. In conclusion, HO-3867 is a p53 mutant–reactivating drug with high clinical anticancer potential.","claims":[{"public_id":"cl_367a387f1cf61cb3667a64969504bda7","status":"active","text":"HO-3867 covalently binds to mutant p53 and initiates a wildtype p53-like anticancer genetic response.","confidence":0.97,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_367a387f1cf61cb3667a64969504bda7"},{"public_id":"cl_fd3f0237cd7cea28131ad2c44e29e56f","status":"active","text":"HO-3867 exhibits high anticancer efficacy in tumor models.","confidence":0.93,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_fd3f0237cd7cea28131ad2c44e29e56f"},{"public_id":"cl_53500fe99876b28f71dbb327b54c2218","status":"active","text":"HO-3867 is a p53 mutant-reactivating drug with high clinical anticancer potential.","confidence":0.9,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_53500fe99876b28f71dbb327b54c2218"},{"public_id":"cl_c65cf404cb103a361d3d5d44bec66fa6","status":"active","text":"HO-3867 is exclusively cytotoxic toward cancer cells.","confidence":0.95,"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/claims/cl_c65cf404cb103a361d3d5d44bec66fa6"}],"concepts":[{"public_id":"co_0f1a025a933007da2d52362608a20f12","status":"active","name":"clinical anticancer potential","description":"The potential of a compound to be developed for cancer treatment in clinical settings.","types":["therapeutic potential"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_0f1a025a933007da2d52362608a20f12"},{"public_id":"co_31f3bee63958442db5dc7e1155020a55","status":"active","name":"wildtype p53-like anticancer genetic response","description":"A gene-expression response resembling the anticancer transcriptional activity associated with normal p53.","types":["biological response","gene expression response"],"aliases":["wildtype p53 response"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_31f3bee63958442db5dc7e1155020a55"},{"public_id":"co_41c9f4a781637a9193fb327f6f2582e2","status":"active","name":"HO-3867","description":"A curcumin analog investigated for its effects on mutant p53 activity and anticancer activity.","types":["compound","drug"],"aliases":["curcumin analog HO-3867"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_41c9f4a781637a9193fb327f6f2582e2"},{"public_id":"co_7c4d8e27a6169725030e245713028cbd","status":"active","name":"p53 mutant-reactivating drug","description":"A therapeutic agent designed to restore transcriptionally active wildtype-like function to mutant p53.","types":["drug mechanism","therapeutic class"],"aliases":["mutant p53-reactivating drug"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_7c4d8e27a6169725030e245713028cbd"},{"public_id":"co_c49c25c524c357cad211f8cc23aec03a","status":"active","name":"cancer cells","description":"Malignant cells from different origins used to assess selective cytotoxicity.","types":["cell type"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_c49c25c524c357cad211f8cc23aec03a"},{"public_id":"co_cc2657522d8cfca2899db205c8e90774","status":"active","name":"mutant p53","description":"An oncogenic altered form of the p53 tumor-suppressor protein found in many cancers.","types":["protein","oncoprotein"],"aliases":["mutated p53"],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_cc2657522d8cfca2899db205c8e90774"},{"public_id":"co_d25444158bf8bd5c742df0d415f4eeb4","status":"active","name":"tumor models","description":"Experimental models of tumors used to evaluate anticancer efficacy in vivo.","types":["experimental model"],"aliases":[],"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"url":"https://sah.borca.ai/concepts/co_d25444158bf8bd5c742df0d415f4eeb4"}],"external_ids":{"DOI":"10.1074/jbc.RA117.000950","ArXiv":null,"PubMed":29382728,"PubMedCentral":"PMC5868245","MAG":2786643981,"DBLP":null,"ACL":null},"open_access":{"is_open_access":true,"pdf_url":"http://www.jbc.org/article/S002192582039801X/pdf","landing_url":"https://www.semanticscholar.org/paper/cf40794b608f0889c4f2db31faa351d71841688a","source":"semantic_scholar","pdf_url_source":"semantic_scholar_open_access_pdf","license":"CCBY","status":"HYBRID","reason":null},"reference_availability":{"status":"available","references_indexed":true,"full_text_available":false,"full_text_source":null,"count_basis":"semantic_scholar_metadata","extraction_status":"not_applicable","reason":null},"source":{"provider":"episteme2","base_corpus":"semantic_scholar_dump","freshness_mode":"unknown","basis":["semantic_scholar_metadata","postgres_metadata"],"limits":["paper metadata is based on indexed upstream scholarly datasets","claims and concepts are available only for extracted papers","absence of claims or concepts means no extracted graph data is available in this response"],"status":"available","degraded":false,"degraded_reasons":[],"diagnostics":{"status":"available","degraded":false,"degraded_reasons":[],"metadata_status":"available","graph_status":"available","abstract_status":"available"},"source_flags":5},"paper_id":635783,"paper_uid":"538225aa-88d6-48ee-84bf-b21c73958c16","canonical_identity":{"paper_id":635783,"paper_uid":"538225aa-88d6-48ee-84bf-b21c73958c16","identity_status":"available","lookup_basis":"semantic_scholar_external_id","compatibility_path":"corpus_id"},"url":"https://sah.borca.ai/papers/4228513"}